Ortho-Chlorination of phenoxy 1,2-dioxetane yields superior chemiluminescence

probes for in vitro and in vivo imaging

Tal Eilon-Shaffer^{a‡}, Michal Roth-Konforti^{a‡}, Anat Eldar-Boock^b, Ronit Satchi-Fainaro^b,


and Doron Shabata*

[‡]T.E.-S. and M.R.-K. contributed equally

^aSchool of Chemistry, Raymond and Beverly Sackler Faculty of Exact Sciences and ^bDepartment of Physiology and Pharmacology, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978 Israel.

Supporting Information

Supplementary Figures	S2
Synthetic Schemes and Experimental Procedures	S8-S13
NMR and MS Spectra of Key CompoundsS2	14-S23
In Vitro Experiments	S24
In Vivo Experiments	S24-S25
References	S25



Supplementary Figures

Figure S1. Fluorescence emission spectra of benzoate esters 1 and 2 [50 μ M] in PBS, different pH and 5% DMSO, Ex: 400 nm.




Figure S2. Single pKa calculation of **benzoate 1b** via Boltzmann fit in Origin software. The absorbance measurements were done in triplicates and the pKa calculated was averaged and taken as the pKa value.




Figure S3. Single pKa calculation of **benzoate 2b** via Boltzmann fit in Origin software. The absorbance measurements were done in triplicates and the pKa calculated was averaged and taken as the pKa value.




Figure S4. Chemiluminescent imaging and signal quantification of probes **1** and **2** [5 μ M] in murine CT26 colon carcinoma cells.




Figure S5. (A) Chemiluminescent kinetic profile for probes **1** and **1a** [100 μ M] upon activation with 1.5 units/mL β -galactosidase in PB pH 5.5, 1% DMSO at 37°C. (B) Chemiluminescent kinetic profile for probes **2** and **2a** [100 μ M] upon activation with 1.5 units/mL β -galactosidase in PB pH 5.5, 1% DMSO at 37°C.




Figure S6. (Top) *in vivo* imaging triplicates of endogenous β -galactosidase in murine CT26 colon carcinoma tumors. Probe **1a**, 100 μ L of 100 μ M was injected intratumorally (IT). (Bottom) Normalized values of signal intensities measured for probe **1a** with CT26-LacZ and CT26-WT.







Figure S7. (Top) *in vivo* imaging triplicates of endogenous β -galactosidase in murine CT26 colon carcinoma tumors. Probe **2a**, 100 μ L of 100 μ M was injected intratumorally (IT). (Bottom) Normalized values of signal intensities measured for probe **2a** with CT26-LacZ and CT26-WT.







Figure S8. (Top) *in vivo* imaging triplicates of endogenous β -galactosidase in CT26 tumors. Probes **1a** and **2a**, 100 µL of 100 µM were injected intratumorally (IT). (Bottom) Normalized values of signal intensities measured for probe **2a** with CT26-LacZ compared to probe **1a** with CT26-LacZ.

General methods

All reactions requiring anhydrous conditions were performed under an Argon atmosphere. All reactions were carried out at room temperature unless stated otherwise. Chemicals and solvents were either A.R. grade or purified by standard techniques. Thin layer chromatography (TLC): silica gel plates Merck 60 F₂₅₄: compounds were visualized by irradiation with UV light. Column chromatography (FC): silica gel Merck 60 (particle size 0.040-0.063 mm), eluent given in parentheses. Reverse-phase high pressure liquid chromatography (RP-HPLC): C18 5u, 250x4.6 mm, eluent given in parentheses. Preparative RP-HPLC: C18 5u, 250x21mm, eluent given in parentheses. ¹H-NMR spectra were measured using Bruker Avance operated at 400MHz. ¹³C-NMR spectra were measured using Bruker Avance operated at 100 MHz. Chemical shifts were reported in ppm on the δ scale relative to a residual solvent (CDCl3: δ = 7.26 for 1H-NMR and 77.16 for 13C-NMR, DMSO-d6: δ = 2.50 for 1H-NMR and 39.52 for 13C-NMR). Mass spectra were measured on Waters Xevo TQD. Chemiluminescence was recorded on Molecular Devices Spectramax i3x. All general reagents, including salts and solvents, were purchased from Sigma-Aldrich. Light irradiation for photochemical reactions: LED PAR38 lamp (19W, 3000K).

Abbreviations. ACN-Acetonitrile, DCM-Dichlorometane, DIPEAdiisopropylethylamine, DMF- N,N'-Dimethylformamide, Et₂O- diethylether, Et₃N-Triethylamine, EtOAc-Ethylacetate, HBTU-2-(1H-benzotriazol-1-yl)-1,1,3,3tetramethyluronium hexafluorophosphate, K₂CO₃- potassium carbonate, MeOH-Methyl alcohol, NH₄Cl- ammonium chloride, Na₂S₂O₃- Sodium Thiosulfate, Na₂SO₄-Sodium Sulfate, TMS-CI - Trimethylsilyl chloride, TFA- Trifluoroacetic acid, TIPS-Triisopropylsilane

S8



Compound 3a


Enol ether **3**^[1] (120 mg, 0.147 mmol, 1 eq), LiOH (21.3 mg, 0.887 mmol, 6 eq) were dissolved in 2 ml of of 4:1 solution THF:H₂O. Reaction mixture was stirred at room temperature and monitored via RP-HPLC. Upon completion, reaction mixture was diluted with EtOAc and washed with saturated aqueous NH₄Cl solution followed by brine. Organic phase was dried over Na₂SO₄ and concentrated under reduced pressure to afford 64 mg (68% yield) of off-white solid. ¹H NMR (400 MHz, CDCl3) δ 7.95 – 7.84 (m, J = 16.1 Hz, 1H), 7.41 (d, J = 8.0 Hz, 1H), 7.26 (d, J = 8.6 Hz, 2H), 7.01 (d, J = 8.5 Hz, 2H), 6.89 (s, 1H), 6.84 (d, J = 7.6 Hz, 1H), 6.39 (d, J = 16.1 Hz, 1H), 4.91 (s, 2H), 4.84 (d, J = 7.6 Hz, 1H), 3.99 (d, J = 6.4 Hz, 2H), 3.90 – 3.82 (m, 1H), 3.81 – 3.68 (m, J = 9.7, 5.0 Hz, 3H), 3.69 – 3.58 (m, J = 16.1, 7.9 Hz, 2H), 3.21 (s, 3H), 3.16 (s, 1H), 2.61 (s, 1H), 1.93 – 1.68 (m, 12H). ¹³C NMR (101 MHz, CDCl3) δ 229.19, 190.05, 174.44, 170.37, 157.42, 157.17, 142.84, 140.80, 139.15, 133.77, 130.46, 129.34, 128.53, 122.66, 122.30, 118.13, 116.86, 113.12, 101.15, 74.85, 73.28, 70.98, 70.25, 68.81, 61.19, 58.00, 39.20, 39.04, 37.07, 32.42, 30.44, 29.71, 28.22, 20.75. MS (ES-): *m/z* calc. for C₃₄H₄₀O₁₀: 608.26 ; found: 607.4 [M-H]⁻.



Compound 3b

Compound **3a** (150 mg, 0.246 mmol, 1 eq) was dissolved in 1.5 ml of DCM and cooled to 0°C. N-hydroxysuccinimide (57 mg, 0.49 mmol, 2 eq) was added followed by N,N'-Dicyclohexylcarbodiimide (76 mg, 0.37 mmol, 1.5eq). The reaction was allowed to warm up to room temperature and monitored by RP-HPLC. Upon completion, 5 ml of DCM were added, followed by catalytic amount of methylene


blue. Oxygen was bubbled through the solution, while irradiating with yellow light. The reaction was monitored by RP-HPLC (50-100% ACN in water, 20 min). Upon completion, the reaction mixture was concentrated by evaporation under reduced pressure and the crude product was purified by preparative RP-HPLC (50-100% ACN in water, 20 min) to afford compound **3b** (61 mg, 34% yield) as a white solid. ¹H NMR (400 MHz, CDCl₃+MeOD) δ 8.10 (d, *J* = 16.2, 1H), 7.49 (d, *J* = 18.9 Hz, 1H), 7.45 – 7.14 (m, 3H), 7.15 – 6.81 (m, 3H), 6.67 (d, *J* = 16.2 Hz, 1H), 5.07 (m, 2H), 4.79 (d, *J* = 7.6 Hz, 1H), 3.99 – 3.75 (m, 6H), 3.75 – 3.65 (m, 2H), 3.58 (d, *J* = 6.4 Hz, 2H), 3.11 (s, 3H), 2.91 (s, 1H), 2.75 (s, 3H), 1.98 (s, 1H), 1.92 (s, 1H), 1.66 (m, 9H), 1.38 (d, *J* = 11.6 Hz, 1H), 1.28 – 1.18 (m, 1H), 1.14 (d, *J* = 12.9 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃+MeOD) δ 170.17, 162.69, 157.78, 157.33, 144.77, 139.64, 129.94, 129.79, 129.20, 123.59, 116.86, 113.04, 111.72, 101.19, 95.81, 74.83, 73.40, 70.91, 70.41, 68.66, 61.13, 50.01, 36.22, 34.72, 33.56, 33.18, 33.09, 32.22, 31.67, 31.48, 25.94, 25.76, 25.62, 25.49, 24.85. MS (ES+): *m/z* calc. for C₃₈H₄₃NO₁₄: 737.75; found: 760.6 [M+Na]⁺.



Probe 1a

Compound $3c^{[2]}$ (54 mg, 0.073 mmol, 1 eq) and compound 3b (27 mg, 0.08 mmol, 1 eq) were dissolved in DMF (0.5 ml) and a few drops of Et₃N were added. The Reaction was monitored by RP-HPLC (30-100% ACN in water, 20 min). Upon completion, **CGKRK**^[3] (92 mg, 0.088 mmol, 1.2 eq) was added. The Reaction was monitored by RP-HPLC (30-100% ACN in water, 20 min). Upon completion, the

reaction mixture was concentrated by evaporation under reduced pressure. The crude product was purified by preparative RP-HPLC (30-100% ACN in water, 20 min) to afford compound **probe 1a** (36 mg, 25% yield) as a white solid. HRMS (ES-): m/z calc. for C₇₃H₁₁₁N₁₃O₂₂S: 1553.73; found: MH⁺ 1554.7772.



Compound 4a


Enol ether **4**^[1] (120 mg, 0.147 mmol, 1 eq), LiOH (21.3 mg, 0.887 mmol, 6 eq) were dissolved in 2 ml of of 4:1 solution THF:H₂O. Reaction mixture was stirred at room temperature and monitored via RP-HPLC. Upon completion, reaction mixture was diluted with EtOAc and washed with saturated aqueous solution NH₄Cl followed by brine. Organic phase was dried over Na₂SO₄ and concentrated under reduced pressure to afford 64 mg (68% yield) of yellow solid. ¹H NMR (400 MHz, CDCl3) δ 7.95 – 7.84 (m, J = 16.1 Hz, 1H), 7.41 (d, J = 8.0 Hz, 1H), 7.26 (d, J = 8.6 Hz, 2H), 7.01 (d, J = 8.5 Hz, 2H), 6.89 (s, 1H), 6.84 (d, J = 7.6 Hz, 1H), 6.39 (d, J = 16.1 Hz, 1H), 4.91 (s, 2H), 4.84 (d, J = 7.6 Hz, 1H), 3.99 (d, J = 6.4 Hz, 2H), 3.90 – 3.82 (m, 1H), 3.81 – 3.68 (m, J = 9.7, 5.0 Hz, 3H), 3.69 – 3.58 (m, J = 16.1, 7.9 Hz, 2H), 3.21 (s, 3H), 3.16 (s, 1H), 2.61 (s, 1H), 1.93 – 1.68 (m, 12H). ¹³C NMR (101 MHz, CDCl₃) δ 169.83, 157.47, 153.79, 140.13, 139.46, 138.22, 132.53, 130.98, 130.08, 129.82, 129.62, 127.79, 124.88, 119.21, 116.93, 100.95, 74.74, 73.92, 73.27, 72.36, 71.18, 70.01, 69.18, 64.50, 61.42, 39.14, 38.70, 37.70, 37.07, 35.61, 33.91, 30.26, 29.76, 29.03, 28.26. MS (ES-): *m/z* calc. for C₃₄H₃₉ClO₁₀: 642.22 ; found: 641.5 [M-H]⁻.



Compound 4b

Compound **4a** (209 mg, 0.323 mmol, 1 eq) was dissolved in 1.5 ml of DCM and cooled to 0°C. N-hydroxysuccinimide (75 mg, 0.634 mmol, 2 eq) was added followed by N,N'-Dicyclohexylcarbodiimide (100 mg, 0.488 mmol, 1.5eq). The reaction was allowed to warm up to room temperature and monitored by RP-hplc. Upon completion, 5 ml of DCM were added, followed by catalytic amount of methylene blue. Oxygen was bubbled through the solution, while irradiating with yellow light. The reaction was monitored by RP-HPLC (50-100% ACN in water, 20 min). Upon completion, the reaction mixture was concentrated by evaporation under reduced pressure and the crude product was purified by preparative RP-HPLC (50-100% ACN in water, 20 min) to afford compound **4b** (138 mg, 59% yield) as a white solid. ¹H NMR (400 MHz, CDCl₃+MeOD) δ 7.93 – 7.83 (m, 2H), 7.52 (d, *J* = 8.3 Hz, 1H), 7.21 (d, *J* = 8.1 Hz, 2H), 6.96 (d, *J* = 8.1 Hz, 2H), 6.47 (d, *J* = 16.3 Hz, 1H), 4.94 – 4.78 (m, 2H), 3.94 (s, 1H), 3.82 – 3.49 (m, 8H), 3.16 (s, 3H), 2.95 (s, 1H), 2.81 (s, 4H), 2.25 (d, *J* = 11.5 Hz, 1H), 1.92 (s, 1H), 1.80 – 1.49 (m, 8H), 1.41 (d, *J* = 12.4 Hz, 1H), 1.24 (dd, *J* = 24.2, 12.8 Hz, 2H).

¹³C NMR (101 MHz, CDCl₃+MeOD) δ 170.10, 161.77, 157.85, 154.61, 143.63, 136.49, 130.89, 129.42, 129.01, 127.92, 125.51, 116.79, 114.34, 111.73, 101.14, 96.55, 76.34, 74.88, 73.29, 70.98, 68.88, 61.40, 36.48, 33.87, 33.58, 32.59, 32.15, 31.52, 26.11, 25.78, 25.63. MS (ES+): *m/z* calc. for C₃₈H₄₂ClNO₁₄: 771.23; found: 772.6 [M+H]⁺.





Probe 2a


Compound **4c**^[2] (5.3 mg, 0.015 mmol, 1 eq) and compound **4b** (10 mg, 0.013 mmol, 1 eq) were dissolved in DMF (0.5 ml) and a few drops of Et₃N were added. The Reaction was monitored by RP-HPLC (30-100% ACN in water, 20 min). Upon completion, **CGKRK**^[3] (15 mg, 0.014 mmol, 1.1 eq) was added. The Reaction was monitored by RP-HPLC (30-100% ACN in water, 20 min). Upon completion, the reaction mixture was concentrated by evaporation under reduced pressure. The crude product was purified by preparative RP-HPLC (30-100% ACN in water, 20 min) to afford compound **probe 2a** (16.2 mg, 61% yield) as a white solid. HRMS (ES-): *m/z* calc. for C₇₃H₁₁₀ClN₁₃O₂₂S: 1587.73; found: MH⁺ 1588.7365.

H-NMR, C-NMR, MS and/or HPLC Spectra of Key Compounds


Compound 3a









Compound 3b











Chemical Formula: C₇₃H₁₁₁N₁₃O₂₂S Exact Mass: 1553.77 Molecular Weight: 1554.82


ő



RP-HPLC chromatogram of probe **1a** (λ = 270 nm). C18 column. Eluent: 30%-90% ACN in H2O (0.1% TFA).


Compound 4a







S20

Compound 4b




Probe 2a









RP-HPLC chromatogram of probe **2a** (λ = 270 nm). C18 column. Eluent: 30%-90% ACN in H2O (0.1% TFA).

In vitro Experiments

Cell Culture

Murine colon carcinoma CT26.wt and CT26.CL5 cells were purchased from the American Type Culture Collection (ATCC Manassas, VA, USA). CT26.WT cell line was cultured in RPMI 1640 growing media supplemented with 10% FBS, 100 μ g/mL streptomycin, 100 units/mL penicillin, 12.5 units/mL nystatin and 2 mM L-glutamine. CT26.CL25 cell line was cultured in RPMI 1640 growing media supplemented with 10% FBS, 100 μ g/mL streptomycin, 100 units/mL penicillin, 12.5 units/mL penicillin, 12.5 units/mL nystatin, 2 mM L-glutamine, 4.5 g/L glucose, 10 mM HEPES and 1.0 mM sodium pyruvate and supplemented with 0.1 mM non-essential amino-acids and 0.4 mg/ml G418. Cells were grown at 37°C; 5% CO2.

Chemiluminescence imaging in living cells

CT26.wt and CT26.CL5 cells (40,000 cells/well) were seeded in 96 well corning clear bottom plates with their growth medium. Following 24 h, medium was replaced and to a fresh growth medium with materials **1**, **1a**, **2**, **2a** [5 μ M]. Cells were immediately imaged using BioSpace Lab PhotonIMAGERTM for 30 min. The experiment was repeated 3 times.

In vivo Experiments

Ethics Statement

All animal procedures were performed in compliance with Tel Aviv University, Sackler School of Medicine (Tel Aviv, Israel) guidelines, and protocols were approved by the Tel Aviv University Institutional Animal Care and Use Committee (IACUC).

Intravital non-invasive chemiluminescence imaging

Six 7-weeks old BALB/c female mice (Harlan Laboratories Israel Ltd., Jerusalem, Israel) were anesthetized using a mixture of ketamine (100 mg/kg) and xylazine (12 mg/kg) injected subcutaneously. Then, mice were injected subcutaneously with 50 μ L of the materials **1**, **1a**, **2** or **2a**, previously incubated in PBS 7.4 (in the presence or absence of betagalactosidase) for 30 min. The mice were imaged and

chemiluminescence was monitored for up to 30 min by intravital non-invasive bioluminescence imaging system (Photon Imager; Biospace Lab, Paris, France). Images were obtained by Photo-Acquisition software (Biospace Lab) and analyzed by M3Vision Software (Biospace Lab). In addition, 30 6-weeks old BALB/c female mice (Harlan Laboratories Israel Ltd., Jerusalem, Israel) were inoculated subcutaneously with 1*10⁶ murine CT26 cells. 15 mice were inoculated with CT26-wt and 15 with CT26.Cl25. tumor growth was monitored q.o.d. until tumors were ~ 350 mm³. Mice were anesthetized using a mixture of ketamine (100 mg/kg) and xylazine (12 mg/kg) injected subcutaneously. Then, mice were injected with 100 μ L of the materials A, B, C or D, or saline control by intra-tumoral injection. The mice were imaged and chemiluminescence was monitored for up to 30 min by intravital non-invasive bioluminescence imaging system (Photon Imager; Biospace Lab, Paris, France). Images were obtained by Photo-Acquisition software (Biospace Lab) and analyzed by M3Vision Software (Biospace Lab).

Chemiluminescence signal was quantified as total signal of photons/exposure time (sec)/ tumor size (mm³). Data is expressed as mean ± S.D.

References

- [1] O. Green, T. Eilon, N. Hananya, S. Gutkin, C. R. Bauer, D. Shabat, ACS Cent. Sci.
 2017, 3, 349–358.
- [2] Chem. Biol. **2011**, 18, 1261–1272.
- [3] D. Shabat, M. Roth-Konforti, C. Bauer, Angew. Chemie Int. Ed. 2017, DOI 10.1002/anie.201709347.